查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529693

北美生物技術和製藥服務外包市場規模、佔有率和趨勢分析報告：按服務、最終用途、國家和細分市場預測，2024-2030 年

North America Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End Use, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

北美生物技術和製藥服務外包市場成長和趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，北美生物技術和醫藥服務外包市場規模預計將達到168.1億美元，2024年至2030年複合年成長率為5.13%。

將具有更高投資回報率的新分子推向市場的競爭日益激烈，預計將增加全球對 CRO服務供應商的需求。製藥公司面臨著不斷增加的研究成本和監管複雜性，產生了對跨多個產品組合的專業知識的需求，並增加了市場外包的需求。隨著臨床試驗日益私有化，為了專注於核心功能，外包給 CRO 和 CDMO 的情況正在增加。製藥和生技公司開始外包需要複雜且嚴格的進度管理的研發業務。 CRO 的功能是按照客戶指定的時間表將新產品推向市場。 CRO 擁有必要的基礎設施和熟練的專業知識，並具有與成本、時間和效率相關的多種優勢。成本節省有助於為申辦者和患者提供最佳的節省。

藥物發現和開發是製藥和生物技術公司採用的基本策略。慢性和長期疾病的增加導致藥物開發過程中對廣泛研發投資的需求增加。臨床試驗失敗率的增加，加上藥物開發成本的增加，導致製造商遭受重大收益損失。臨床試驗受挫導致中小型藥廠破產。許多私人公司決定，如果他們擾亂開發新藥過程，他們將不再獲得創投支持。為了避免這種情況並獲得可觀的投資收益，製藥公司現在正在採用基於計算生物學的預測模型，而不是傳統的臨床試驗方法，以提高預計促進成長的市場表現。從專家、研發主管和臨床專家那裡獲得的見解可以幫助公司節省大量可用於研發的資金，從而推動對諮詢服務的需求。

醫療保健外包產業近期併購活動迅速增加。該領域的快速成長和廣泛的潛力吸引了製藥公司、生物技術公司和創業投資的大量投資。因此，公司希望透過策略性收購來擴大其產品組合和能力，並利用新的商機來增強其在市場上的競爭力。例如，2024 年 5 月，Sartorius AG 宣布與 NVIDIA 合作，利用 NVIDIA 的 AI 驅動的計算軟體和平台支援新治療方法的開發。此外，與開發療法相關的複雜性和高成本導致了產業內合作和整合的增加。併購可以為公司提供互補的技術、專業知識和資源，使他們能夠克服開發挑戰，縮短產品開發時間並增強製造能力。

北美生物技術和製藥服務外包市場報告亮點

  • 按服務分類，諮詢業在 2023 年收益佔有率最大。該行業的顯著成長是由於擴大採用諮詢服務來滿足監管合規、品質保證、改進問題和贊助商的策略諮詢要求。此外，製藥和生物技術公司面臨的主要挑戰，例如詐欺案例增加、智慧財產權（IPR）衝突和技術創新不斷增加，導致監管諮詢服務的廣泛使用。推動諮詢服務需求的另一個因素是市場整合，導致合資企業、收購和合併的增加。這些因素預計將推動市場成長。
  • 根據最終用途，製藥公司部門在 2023 年佔據最大收益佔有率，超過 57.79%。製藥公司越來越傾向於將臨床試驗、資料管理、監管合規和製造等非核心業務外包給 CRO 和 CMO，預計將推動該領域的收益成長。與維持大量的內部能力相比，外包給 CRO 或 CMO 為製藥公司提供了一個具有成本效益的解決方案。
  • 在生技和醫藥服務外包市場，2023年美國將佔87.37%的佔有率。該國的收益成長是由臨床試驗的高研發費用推動的，這也是預計推動市場成長的關鍵因素。例如，2021 年 10 月，美國FDA核准了11 項新的臨床試驗研究，在未來四年內籌集了超過 2,500 萬美元的資金。這些津貼旨在支持專門用於治療罕見疾病的新醫療產品的開發。這些公司的不斷增加擴大了生產能力，以滿足不斷成長的藥品需求，預計將推動市場成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章北美生物技術和製藥服務外包市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
  • 技術景觀
  • 定價模式分析
  • GxP 概述
  • 臨床試驗量分析（2023）
  • 研發投入分析
  • 北美生技與製藥服務外包市場分析工具
  • COVID-19 影響分析

第4章北美生物技術和製藥服務外包市場：按服務分類的估計和趨勢分析

  • 細分儀表板
  • 北美生物技術和製藥服務外包市場：按服務分類的變化分析
  • 2018-2030 年北美生技及製藥服務外包市場規模及趨勢分析（依服務）
  • 諮詢
  • 監管業務
  • 產品設計與開發
  • 審核與評估
  • 產品維護
  • 培訓和教育
  • 其他

第5章北美生物技術和製藥服務外包市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 北美生物技術和製藥服務外包市場：最終用途的變化分析
  • 2018-2030 年北美生物技術和製藥服務外包市場規模和趨勢分析（按最終用途）
  • 製藥公司
  • 生技公司

第6章北美生物技術和製藥服務外包市場：按國家、服務、最終用途分類的估計和趨勢分析

  • 國家儀表板
  • 北美生物技術和製藥服務外包市場：國家差異分析
  • 美國
  • 加拿大
  • 墨西哥
  • 波多黎各

第7章 競爭格局

  • 公司分類
    • 市場領導
    • 新興企業
  • 2023 年企業市場佔有率/估值分析
  • 服務熱圖分析
  • 公司簡介
    • Parexel International Corporation
    • The Quantic Group
    • IQVIA
    • Lachman Consultant Services, Inc.
    • GMP Pharmaceuticals Pty Ltd.
    • LabCorp
    • Charles River Laboratories
    • ICON plc.
    • Syneos Health
    • Lonza
    • Catalent Inc.
    • Samsung Biologics
Product Code: GVR-4-68040-330-1

North America Biotechnology and Pharmaceutical Services Outsourcing Market Growth & Trends:

The North America biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 16.81 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 5.13% from 2024 to 2030.

Increasing competition to launch novel molecules with better RoI is expected to heighten the demand for CRO service providers across the globe. Pharmaceutical companies face complexity in regulations along with increased research costs, creating a need for expertise in numerous portfolios and driving the need for outsourcing in the market. With increasing clinical trial privatization, there has been an increase in outsourcing functions to CROs and CDMOs to focus on core capabilities. Pharmaceutical and biotechnology companies have started outsourcing R&D activities, which are complex and need a strict timeline to follow up. A CRO's function is to bring new products to the market as per the timeline given by the client. CROs have the required infrastructure and skilled expertise, which provides several advantages associated with cost, time, and efficiency. The cost saved helps in offering the best savings for sponsors and patients.

Drug discovery and development is an integral strategy adopted by pharmaceutical and biotechnology companies. An increase in the prevalence of chronic and long-term diseases led to a rise in the demand for extensive R&D investments in the drug development process. Growing clinical trial failure rates coupled with increasing drug development costs lead to huge losses in revenue for manufacturers. Setbacks faced in clinical studies have led smaller pharmaceutical companies to go bankrupt. Many private investors have been observed to withdraw venture capital support from startup drug companies, considering their investments would suffer if there were a disruption in the drug development process. To circumvent these situations and gain a substantial return on investment, pharmaceutical companies are now adopting computational biology-based predictive models over traditional methods of clinical trials, which are expected to drive market growth during the forecast period. Insights gained from subject-matter experts, R&D executives, and clinical professionals help a company save a large amount, which can be spent on R&D, thereby boosting demand for consulting services.

The healthcare outsourcing industry has recently witnessed a surge in mergers and acquisitions. The sector's rapid growth and promising potential have attracted significant investment from pharmaceutical companies, biotech firms, & venture capitalists. As a result, companies seek to expand their portfolios and capabilities through strategic acquisitions to capitalize on emerging opportunities and strengthen their competitive position in the market. For instance, in May 2024, Sartorius AG announced a collaboration with NVIDIA to help the development of new therapies, leveraging NVIDIA's AI-powered computing software and platform. Moreover, the complexity and high costs associated with developing therapeutics are leading to increased collaboration & consolidation within the industry. Mergers & acquisitions offer companies complementary technologies, expertise, and resources, enabling them to overcome development challenges, accelerate product development timelines, and enhance manufacturing capabilities.

North America Biotechnology And Pharmaceutical Services Outsourcing Market Report highlights

  • Based on service, the consulting segment held the largest revenue share in 2023. The large segment growth is owing to the growing adoption of consulting services to meet regulatory compliance, quality assurance, remediation challenges, and strategic consulting requirements by sponsors. Furthermore, regulatory consulting services are widely used owing to increasing fraud cases, discrepancies in Intellectual Property Rights (IPR), and rising technological innovation, which are some of the major challenges faced by pharmaceutical and biotechnology companies. Another factor driving the demand for consulting services is the consolidated nature of the market, which leads to an increase in the number of joint ventures, takeovers, acquisitions, and mergers. Such factors are anticipated to drive the market growth.
  • Based on end use, the pharmaceutical companies segment held the largest revenue share of over 57.79% in 2023. The segment growth is owing to an increasing preference for outsourcing non-core activities such as clinical trials, data management, regulatory compliance, and manufacturing to CROs and CMOs among pharmaceutical companies is anticipated to boost segment revenue growth. Outsourcing to CROs and CMOs provides pharmaceutical companies with cost-effective solutions compared to maintaining extensive in-house capabilities.
  • The U.S. dominated the biotechnology and pharmaceutical services outsourcing market with a share of 87.37% in 2023. The country's revenue growth is owing to high R&D spending on clinical trials, which is another major factor expected to fuel market growth. For instance, in October 2021, the U.S. FDA approved 11 new clinical trial research, resulting in over USD 25 million in funding over the next four years. These grants aim to support the development of new medical products specifically for treating rare diseases. The growing presence of these companies expanding their manufacturing capabilities to cater to the rising demand for pharmaceuticals is anticipated to propel market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Details of primary research
  • 1.6. Market Formulation & Validation
  • 1.7. Country-wise Market Calculation
    • 1.7.1. Country Wise Market: Base Estimates
    • 1.7.2. CAGR Calculation
    • 1.7.3. Country Based Segment Share Calculation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
    • 1.8.2. Value Chain-Based Sizing & Forecasting (Model 2)
    • 1.8.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.8.4. Bottom-up Approach (Model 4)
  • 1.9. Research Scope and Assumptions
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. List of Abbreviations
  • 1.13. Objectives
    • 1.13.1. Objective 1
    • 1.13.2. Objective 2
    • 1.13.3. Objective 3
    • 1.13.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Outsourcing of R&D Activities
      • 3.2.1.2. Changing Regulatory Landscape
      • 3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and Biotechnology Companies
      • 3.2.1.4. Growing Drug Development Costs Coupled With High Clinical Development Failure Rates
      • 3.2.1.5. Increasing Mergers and Collaborations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Monitoring Issues and Lack of Standardization
      • 3.2.2.2. Loss of Control
      • 3.2.2.3. Data Security Issues
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. GxP Overview
    • 3.5.1. Good Manufacturing Practices (GMP)
    • 3.5.2. Current Good Manufacturing Practices (cGMP)
    • 3.5.3. Good Laboratory Practices (GLP)
    • 3.5.4. Good Clinical Practices (GCP)
    • 3.5.5. Good Distribution Practices (GDP)
  • 3.6. Clinical Trials Volume Analysis (2023)
    • 3.6.1. Total Number of Clinical Trials, by Country
    • 3.6.2. Total Number of Clinical Trials, by Phase
    • 3.6.3. Total Number of Clinical Trials, by Study Design
    • 3.6.4. Total Number of Clinical Trials, by Key Therapeutic Area
  • 3.7. R&D Investment Analysis
  • 3.8. North America Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
    • 3.8.1. Porter's Five Forces Analysis
    • 3.8.2. PESTEL Analysis
  • 3.9. COVID-19 Impact Analysis

Chapter 4. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
  • 4.3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 4.4. Consulting
    • 4.4.1. Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Regulatory Consulting
      • 4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Clinical Development Consulting
      • 4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Strategic Planning & Business Development Consulting
      • 4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Quality Management Systems Consulting
      • 4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Regulatory Affairs
    • 4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Legal Representation
      • 4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Regulatory Writing & Publishing
      • 4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Product Registration & Clinical Trial Applications
      • 4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Regulatory Submissions
      • 4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.6. Regulatory Operations
      • 4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.7. Others
      • 4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Product Design & Development
    • 4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. Research, Strategy, & Concept Generation
      • 4.6.2.1. Research, Strategy, & Concept Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. Concept & Requirements Development
      • 4.6.3.1. Concept & Requirements Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4. Detailed Design & Process Development
      • 4.6.4.1. Detailed Design & Process Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5. Design Verification & Validation
      • 4.6.5.1. Design Verification & Validation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.6. Process Validation & Manufacturing Transfer
      • 4.6.6.1. Process Validation & Manufacturing Transfer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.7. Production & Commercial Support
      • 4.6.7.1. Production & Commercial Support Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Auditing and Assessment
    • 4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.2. General Auditing
      • 4.7.2.1. General Auditing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.3. Gap Assessments
      • 4.7.3.1. Gap Assessments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.4. Due Diligence Assessments
      • 4.7.4.1. Due Diligence Assessments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.5. Mock Audits/Inspections
      • 4.7.5.1. Mock Audits/Inspections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.6. Inspection/Audit Management and Support
      • 4.7.6.1. Inspection/Audit Management and Support Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.7. Others
      • 4.7.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Product Maintenance
    • 4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Training & Education
    • 4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. North America Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
  • 5.3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
  • 5.4. Pharmaceutical Companies
    • 5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biotech Companies
    • 5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Country Estimates & Trend Analysis, by Service, by End-Use

  • 6.1. Country Dashboard
  • 6.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Country Movement Analysis
  • 6.3. U.S.
    • 6.3.1. Key Country Dynamics
    • 6.3.2. Competitive Scenario
    • 6.3.3. Regulatory Framework
    • 6.3.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Canada
    • 6.4.1. Key Country Dynamics
    • 6.4.2. Competitive Scenario
    • 6.4.3. Regulatory Framework
    • 6.4.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Mexico
    • 6.5.1. Key Country Dynamics
    • 6.5.2. Competitive Scenario
    • 6.5.3. Regulatory Framework
    • 6.5.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Puerto Rico
    • 6.6.1. Key Country Dynamics
    • 6.6.2. Competitive Scenario
    • 6.6.3. Regulatory Framework
    • 6.6.4. Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
    • 7.1.1. Market Leaders
    • 7.1.2. Emerging Players
  • 7.2. Company Market Share/Assessment Analysis, 2023
  • 7.3. Service Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Parexel International Corporation
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Service Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. The Quantic Group
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Service Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. IQVIA
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Service Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Lachman Consultant Services, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Service Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. GMP Pharmaceuticals Pty Ltd.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Service Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. LabCorp
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Service Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Charles River Laboratories
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Service Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. ICON plc.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Service Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Syneos Health
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Service Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Lonza
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Service Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Catalent Inc.
      • 7.4.11.1. Company Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Service Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. Samsung Biologics
      • 7.4.12.1. Company Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Service Benchmarking
      • 7.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 4 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 5 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 6 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 7 North America Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)
  • Table 8 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 9 North America Biotechnology and Pharmaceutical Services Outsourcing by Region, 2018 - 2030 (USD Million)
  • Table 10 North America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 11 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 12 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 13 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 14 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 15 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 16 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 17 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 18 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 19 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 20 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)
  • Table 21 U.S. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 22 Canada Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 23 Canada Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 24 Canada Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 25 Canada Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 26 Canada Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)
  • Table 27 Canada Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 28 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 29 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 30 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 31 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 32 Mexico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 33 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 34 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 35 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 36 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 37 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)
  • Table 38 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 North America Biotechnology and Pharmaceutical Services Outsourcing, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 North America Biotechnology and Pharmaceutical Services Outsourcing, for Consulting, 2018 - 2030 (USD Million)
  • Fig. 13 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 14 North America Biotechnology and Pharmaceutical Services Outsourcing, for Clinical Development Consulting, 2018 - 2030 (USD Million)
  • Fig. 15 North America Biotechnology and Pharmaceutical Services Outsourcing, for Strategic Planning & Business Development Consulting, 2018 - 2030 (USD Million)
  • Fig. 16 North America Biotechnology and Pharmaceutical Services Outsourcing, for Quality Management Systems Consulting, 2018 - 2030 (USD Million)
  • Fig. 17 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 18 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Affairs, 2018 - 2030 (USD Million)
  • Fig. 19 North America Biotechnology and Pharmaceutical Services Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 20 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 21 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 22 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 23 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 24 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Design & Development, 2018 - 2030 (USD Million)
  • Fig. 26 North America Biotechnology and Pharmaceutical Services Outsourcing, for Research, Strategy, & Concept Generation, 2018 - 2030 (USD Million)
  • Fig. 27 North America Biotechnology and Pharmaceutical Services Outsourcing, for Concept & Requirements Development, 2018 - 2030 (USD Million)
  • Fig. 28 North America Biotechnology and Pharmaceutical Services Outsourcing, for Detailed Design & Process Development, 2018 - 2030 (USD Million)
  • Fig. 29 North America Biotechnology and Pharmaceutical Services Outsourcing, for Design Verification & Validation, 2018 - 2030 (USD Million)
  • Fig. 30 North America Biotechnology and Pharmaceutical Services Outsourcing, for Process Validation & Manufacturing Transfer, 2018 - 2030 (USD Million)
  • Fig. 31 North America Biotechnology and Pharmaceutical Services Outsourcing, for Production & Commercial Support, 2018 - 2030 (USD Million)
  • Fig. 32 North America Biotechnology and Pharmaceutical Services Outsourcing, for Auditing and Assessment, 2018 - 2030 (USD Million)
  • Fig. 33 North America Biotechnology and Pharmaceutical Services Outsourcing, for General Auditing, 2018 - 2030 (USD Million)
  • Fig. 34 North America Biotechnology and Pharmaceutical Services Outsourcing, for Gap Assessments, 2018 - 2030 (USD Million)
  • Fig. 35 North America Biotechnology and Pharmaceutical Services Outsourcing, for Due Diligence Assessments, 2018 - 2030 (USD Million)
  • Fig. 36 North America Biotechnology and Pharmaceutical Services Outsourcing, for Mock Audits/Inspections, 2018 - 2030 (USD Million)
  • Fig. 37 North America Biotechnology and Pharmaceutical Services Outsourcing, for Inspection/Audit Management and Support, 2018 - 2030 (USD Million)
  • Fig. 38 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 39 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Maintenance, 2018 - 2030 (USD Million)
  • Fig. 40 North America Biotechnology and Pharmaceutical Services Outsourcing, for Training & Education, 2018 - 2030 (USD Million)
  • Fig. 41 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 42 North America Biotechnology and Pharmaceutical Services Outsourcing, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 43 North America Biotechnology and Pharmaceutical Services Outsourcing, for Biotech Companies, 2018 - 2030 (USD Million)
  • Fig. 44 Country Outlook, 2023 & 2030
  • Fig. 45 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)